Post by Dicot Pharma AB

"It has been an intense start to 2026 and Dicot Pharma has maintained the high pace with which we closed the previous year. Following the promising results from the phase 2a study, we have focused on preparations for the subsequent phase 2b study, planned to be conducted in the US and Europe with initiation in the second half of 2026. We have recently announced a planned rights issue, with an already secured amount of SEK 168 million, corresponding to full funding of the phase 2b study", says Dicot Pharma's CEO Elin Trampe. Read more in the interim report for the first quarter of 2026 here: https://lnkd.in/dgqKxhia You can also watch Elin Trampe and Björn Petersson, CFO, present the quarter in a webcast (in Swedish). https://lnkd.in/dx5QUumh